It’s a good time to buy into healthcare

Don't wait for things to settle down in the markets. Max King explains why now's the time to snap up some healthcare bargains.

811-Scientists-1200

Big pharma will buy in their research

The EpiPen controversy, in which pharmaceutical company Mylan was vilified for raising the price of its treatment for allergic reaction by 400%, caused share prices across the healthcare sector to drop sharply. A few days later, promising results from trials of Biogen's aducanumab, a potential breakthrough in the treatment of Alzheimer's, were treated with indifference by investors. When bad news is contagious but good news is ignored, a long-term opportunity for investors usually beckons.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Max King
Investment Writer

Max has an Economics degree from the University of Cambridge and is a chartered accountant. He worked at Investec Asset Management for 12 years, managing multi-asset funds investing in internally and externally managed funds, including investment trusts. This included a fund of investment trusts which grew to £120m+. Max has managed ten investment trusts (winning many awards) and sat on the boards of three trusts – two directorships are still active.

After 39 years in financial services, including 30 as a professional fund manager, Max took semi-retirement in 2017. Max has been a MoneyWeek columnist since 2016 writing about investment funds and more generally on markets online, plus occasional opinion pieces. He also writes for the Investment Trust Handbook each year and has contributed to The Daily Telegraph and other publications. See here for details of current investments held by Max.